JPMorgan US Research Enhanced Index Equity UCITS ETF - USD (acc) is a equity ETF from JPMorgan tracking the US Research Enhanced Index Equity index through physical replication. Domiciled in Ireland and launched in 2018, the fund manages about 10.7 bn € and charges a TER of 0.20% — 20 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
JPMorgan US Research Enhanced Index Equity UCITS ETF - USD (acc) competes with 2 other products on the same index (US Research Enhanced Index Equity): it ranks 1st by fund size and 1st by ongoing cost, with a TER of 0.20% against a group median of 0.20%. It has been listed since 2018, 8 years of track record — the oldest in its comparison group.
On a €10,000 investment the TER costs 20 € a year, and no product in the group costs less.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 40.9% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in USD. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
Irish domicile lets the fund apply the Ireland–US tax treaty, with 15% withholding instead of 30% on US dividends received by the fund.
| NVIDIA Corporation | 8.3% |
| Apple Inc. | 7.1% |
| Microsoft Corporation | 5.6% |
| Amazon.com Inc | 4.5% |
| Alphabet Inc Class A | 3.5% |
| Broadcom Inc | 3.4% |
| Alphabet Inc Class C | 2.6% |
| Meta Platforms Inc. | 2.3% |
| Micron Technology Inc | 1.9% |
| Tesla Inc | 1.7% |
| Borsa Italiana | JREU | EUR |
| XETRA | JREU | EUR |
| Francoforte | JREU | EUR |
| London Stock Exchange | JURE | GBX |
| London Stock Exchange | JREU | USD |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.